64x Bio, a biotech company dedicated to developing scalable solutions for advanced therapies, has officially launched its AAV Apex Suite, a significant advancement aimed at resolving the critical manufacturing bottlenecks currently hindering gene therapy development. Announced from San Francisco, this high-yield product line is designed to facilitate the widespread availability of gene therapies, which, despite their curative potential, have been limited by high costs and insufficient manufacturing scale. The AAV Apex Suite notably includes suspension-adapted HEK293 cell lines coupled with optimized production processes, enabling partners to consistently achieve remarkable viral titers exceeding E15 vg/L. This impressive performance has been independently validated by various partners across diverse serotypes and therapeutic payloads, confirming both high titer and quality. The core challenge for gene therapies has shifted to cost-effective, high-quality manufacturing, making the AAV Apex Suite a crucial milestone. The suite itself is a direct outcome of 64x Bio’s proprietary VectorSelect platform, which leverages an expanding database to map cellular programs driving yield, providing critical genetic and metabolic insights that inform the engineering of cell lines and nutrient formulations for media components. This computational power allows for continuous refinement and accelerated design of future products. The AAV Apex Suite serves as an initial demonstration of the platform's capabilities, with plans already underway for expanding the suite to include stable cell lines and exploring broader applications of VectorSelect for advanced biologics beyond AAV. Reflecting the urgent industry need, five leading global biopharma and CDMOs have already entered strategic collaborations to evaluate the AAV Apex Suite, highlighting its potential to transform gene therapy manufacturing.